Plavix
AttorneyOne.com is a free nationwide legal referral service. We are not a law firm. We help consumers find the best representation for their legal needs.
If you or a loved one are in need of legal assistance concerning Plavix you should get a lawyer on your side immediately. You will pay no attorney fees unless you win your case.
Email up to 10 Plavix law firms in one click; by filling out the simple Free Case Evaluation form.
For additional info on Plavix use the related topic links on the far right.
Plavix In The News
Schering-Plough touts pipeline over competitors'Schering-Plough Corp. has many promising drugs in late testing, three awaiting approval, plus years of patent protection for its key products, unlike most of its competitors, Chief Executive Fred Hassan told analysts Monday.
(AFX UK Focus) 2008-11-27 08:57 UPDATE 2-Sanofi's Multaq to get U.S. panel review in MarchPARIS, Nov 27 (Reuters) - Sanofi-Aventis' experimental heart drug Multaq will be reviewed by an independent expert panel in the United States next March, marking a delay in a priority review by the health regulator. The world's No.3 drugmaker said on Thursday the advisory panel on Multaq, which some analysts forecast could yield more than $2 billion in annual sales, would meet on March 18. ...
Schering-Plough touts pipeline over competitors'Schering-Plough Corp. has many promising drugs in late testing, three awaiting approval, plus years of patent protection for its key products, unlike most of its competitors, Chief Executive Fred Hassan told analysts Monday. The drugmaker has three drugs awaiting U.S. approval and nine more in final human testing - including a new type of anticlotting drug that could grab some of blockbuster ..
(AFX UK Focus) 2008-11-24 16:35 Glance-STOCKS NEWS EUROPE-Premiere up; Fininvest raises stakeSTOCKS NEWS Reuters Results diary Stocks on the move Real-time Equity News
Sinking feeling in the eurozoneThe news from continental Europe has been unremittingly grim in recent weeks.
Schering’s Hassan Looks Past Vytorin, Touts Research (Update2)Nov. 24 (Bloomberg) -- Schering-Plough Corp. plans to begin selling products in the next four years that may generate more than $7 billion in combined annual revenue, lessening the company’s dependence on embattled cholesterol pills.
Sanofi Gains After Morgan Stanley Raises Rating, Price EstimateNov. 24 (Bloomberg) -- Sanofi-Aventis SA , France’s largest drugmaker, increased the most in five weeks in Paris trading after Morgan Stanley analysts raised the rating on the stock to “overweight” from “equal weight.”
Analyst expects aggressive M&A in big pharmaLarge mergers and buyouts may be on the way in the pharmaceutical sector, a Deutsche Bank analyst said, because drug makers can't keep up their current level of spending in the face of expiring patents and conservative regulators.
Sanofi Gains Most Since 1989 on Morgan Stanley Rating (Update1)Nov. 24 (Bloomberg) -- Sanofi-Aventis SA , France’s largest drugmaker, increased the most in 19 years in Paris trading after Morgan Stanley analysts raised the rating on the stock to “overweight” from “equal weight.”
Intellectual PropertyOn November 6, 2008, the Supreme Court released its decision in Apotex Inc. v. Sanofi-Synthelabo Canada Inc. The primary issue before the court was the validity of selection patents.
